Clinical Therapeutics, published by Elsevier, is a highly esteemed peer-reviewed journal that has been pivotal in advancing the field of pharmacology since its inception in 1977. With an impressive impact factor and recognition as Q2 in Pharmacology and Q1 in Medical Pharmacology for 2023, it stands at the forefront of research and discussions on innovative therapeutic strategies and pharmacological advancements. This journal not only caters to a broad audience of researchers and clinicians but also plays a vital role in disseminating critical information that supports the enhancement of patient care and safety. As a repository of high-quality, evidence-based articles, Clinical Therapeutics is a crucial resource for those involved in drug development, medical research, and clinical practice, making it an essential read for anyone dedicated to improving health outcomes through pharmaceutical sciences.

Expert Opinion on Drug Safety is a prestigious academic journal dedicated to advancing knowledge in the fields of drug safety and pharmacology. Published by Taylor & Francis Ltd, this journal serves as an essential resource for researchers and professionals seeking to explore the complexities of drug interactions, adverse effects, and risk management. With an impressive impact factor and recognized as a Q1 journal in both the Medicine (Miscellaneous) and Pharmacology (Medical) categories, it ranks favorably at #78 out of 272 in Scopus, placing it in the 71st percentile among its peers. Operating under a rigorous peer-review process, the journal publishes original research, expert reviews, and opinion pieces that contribute to a deeper understanding of drug safety practices. While not an open access journal, it remains a vital platform for disseminating pivotal findings and fostering scholarly dialogue, ensuring that critical insights reach a global audience. With continuous publication from 2002 to 2024, Expert Opinion on Drug Safety is a key reference for anyone involved in pharmaceutical research, healthcare practice, or drug regulation.

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, published by LIPPINCOTT WILLIAMS & WILKINS, is a leading peer-reviewed journal dedicated to the exploration and advancement of pharmacological therapies related to cardiovascular diseases. With its ISSN 0160-2446 and E-ISSN 1533-4023, this esteemed journal has been at the forefront of cardiovascular research since its inception in 1979, continuously offering insights until 2024. It holds a commendable position in the 2023 category quartiles, classified as Q2 in both Cardiology and Cardiovascular Medicine, as well as Medicine (miscellaneous) and Pharmacology, showcasing its significance within these fields. The journal presents a unique platform for researchers, health professionals, and students to disseminate their findings, fostering an environment of knowledge growth and collaboration in cardiovascular pharmacology. Readers can expect to find high-quality articles that contribute to the body of knowledge in cardiovascular therapies, ensuring they remain informed of the latest advancements and clinical practices. Discover more about this influential publication and its commitment to enhancing cardiovascular health.

DRUGS is a prestigious, peer-reviewed journal published by ADIS INT LTD, specializing in the field of pharmacology across diverse medical applications. With an impressive impact factor and ranking as Q1 in the Pharmacology (Medical) category as per the 2023 metrics, this journal consistently exhibits a strong influence in the medical research community, holding a notable rank of #3 out of 272 in its domain on Scopus, placing it within the 99th percentile. Established in 1971 and converging its insightful contributions until 2024, DRUGS encompasses a broad scope, focusing on the latest advancements in drug research, development, and clinical applications, aiming to bridge the gap between laboratory discoveries and therapeutic practices. Though not an Open Access journal, it remains a key resource for researchers, professionals, and students keen on exploring cutting-edge findings and developments in pharmacology. Its location in the United Kingdom further emphasizes its role as a global leader in pharmaceutical sciences.

Clinical Pharmacology-Advances and Applications is a premier open access journal published by DOVE MEDICAL PRESS LTD, based in New Zealand. Since its establishment in 2009, the journal has been dedicated to advancing the field of pharmacology by disseminating innovative research and applications related to medication therapy and patient outcomes. With its notable impact factor and current ranking within the top percentile of pharmacology journals, it provides an invaluable platform for researchers, healthcare professionals, and students to share knowledge and foster collaboration. The journal's content spans a wide range of topics, ensuring coverage of both fundamental and emerging areas in medical pharmacology. As of 2023, it holds a strong position in the Q2 quartile, underscoring its relevance and influence within the scientific community. Authors and readers alike benefit from its open access model, which ensures that critical findings are widely accessible, thereby enhancing the pace of discovery and application in clinical settings.

British Journal of Clinical Pharmacology, published by Wiley, is a premier peer-reviewed journal that has been at the forefront of pharmacology research since its inception in 1974. Renowned for its high academic rigor, it stands out with an impressive impact factor that places it in the Q1 quartile within both the general pharmacology and medical pharmacology categories. With a Scopus ranking reflecting its esteemed status—ranked #68 out of 272 in medical pharmacology and #109 out of 313 in pharmacology, toxicology, and pharmaceutics—the journal serves as a critical resource for researchers, clinicians, and students who are keen to explore innovations and advancements in drug therapy. The journal's scope encompasses a wide array of topics, including clinical trials, drug safety, and pharmacokinetics, making it an essential platform for disseminating cutting-edge pharmacological findings. Although it does not offer open access, the stringent selection of articles ensures that only the highest-quality research is published, further contributing to the ongoing discourse in clinical pharmacology.

Australian Prescriber is a distinguished open-access journal published by Therapeutic Guidelines Ltd, aiming to advance the field of pharmacology and medical prescriptions. Since its inception in 1994, this journal has been dedicated to disseminating essential findings and insights related to therapeutic guidelines and pharmaceutical care, making it an invaluable resource for healthcare professionals and researchers alike. With an ISSN of 0312-8008 and an E-ISSN of 1839-3942, it caters to an audience that values evidence-based medicine, empowering practitioners with knowledge to enhance clinical practice. The journal currently holds a Q2 ranking in the Pharmacology (medical) category and is recognized in the 51st percentile among its peers, reflecting its significant contributions to the medical field. Available from 1995 to 2024, this journal not only serves as an academic platform but also a critical discussion forum for professionals keen on improving pharmacological practices in Australia and beyond.

Expert Opinion on Investigational Drugs, published by Taylor & Francis Ltd, is a premier journal dedicated to the dissemination of high-quality, peer-reviewed research in the fields of pharmacology and medicine. As an integral part of the scientific community since its inception in 1994, this journal has established itself as a leading source of insightful analysis and expert commentary on emerging drug therapies, providing invaluable resources for researchers, clinicians, and healthcare professionals. With an impressive impact factor and ranking in the top quartile across multiple pharmacological categories, it remains a vital platform for discussing innovative drug developments and their clinical applications. Though it operates on a subscription basis, Expert Opinion on Investigational Drugs is crucial for anyone involved in pharmacological research and the drug development process, positioning itself at the forefront of medical advancements and offering critical insights into the rapid evolution of investigational therapies.

The International Journal of Clinical Pharmacy, published by Springer, serves as a pivotal platform for advancing research in the fields of Pharmaceutical Science and Pharmacology. This esteemed journal, recognized for its significant impact with an impressive Q1 ranking in Pharmacy and multiple Q2 designations, provides a dedicated space for scholars and practitioners to share innovative findings and methodologies that enhance clinical pharmacy practices. With an international reach and publication spanning from 2011 to 2024, the journal aims to facilitate knowledge exchange among researchers, professionals, and students, ultimately contributing to improved therapeutic outcomes. As an open-access journal, it promotes widespread dissemination of vital research, ensuring that cutting-edge clinical pharmacy knowledge is accessible to all stakeholders in the healthcare continuum.

PHARMAZIE is a prestigious, peer-reviewed journal published by AVOXA-MEDIENGRUPPE DEUTSCHER APOTHEKER GMBH, focusing on the dynamic field of pharmaceutical science since its inception in 1947. With its ISSN 0031-7144 and a current impact factor placing it in the Q2 category of Pharmaceutical Science journals, PHARMAZIE has established itself as a pivotal resource for researchers, practitioners, and students alike. The journal emphasizes the dissemination of high-quality, original research in pharmacology, toxicology, and pharmaceutics, contributing to the advancement of knowledge and innovation in these fields. While currently not open access, the journal maintains a commendable Scopus rank of #94 out of 183 in its category, highlighting its relevance and appeal to the academic community. With a commitment to bridging the gap between research and practical applications, PHARMAZIE plays a crucial role in shaping the future of pharmaceutical practices and policies.